169 results about "Kidney cell" patented technology

The invention relates to the technical field of cytology, in particular to a grass carp brain astrocyte line and application thereof, the grass carp brain astrocyte line is preserved in China Center for Type Culture Collection on May 7, 2025, and the preservation number of the grass carp brain astrocyte line is CCTCC NO: C2025149. The grass carp brain astroglia cell line provided by the invention has the capability of efficiently proliferating GCRV-II, and the virus titer of the GCRV-II replicated in the cell line at least can reach 1.38 * 10 < 8 > pfu / mL or above; after the GCRV-II is blindly passed for 5 generations in a grass carp astroglia cell line, the grass carp can still have typical bleeding symptoms and death due to the virus. And the exogenous plasmid transfected grass carp brain astroglia cell line has similar transfection efficiency to commercial grass carp kidney cells. Therefore, the invention lays an important foundation for deep research of pathogenic mechanism of GCRV-II, vaccine preparation, antiviral drug screening and prevention and control of grass carp viral hemorrhagic disease.

The invention belongs to the technical field of biology, and particularly relates to an immortalized alpaca kidney cell line and a construction method and application thereof. The immortalized alpaca kidney cell line disclosed by the invention is named as immortalized alpaca kidney cells (Alpaca kidney cells) BNalpaca 1.0, and the preservation number of the immortalized alpaca kidney cell line is CGMCC (China General Microbiological Culture Collection Center) No.46058. The construction method of the immortalized alpaca kidney cell line comprises the following steps: extracting and culturing alpaca primary kidney cells; infecting alpaca primary kidney cells by using SV40 large T antigen immortalized lentivirus; carrying out resistance screening on the immortalized alpaca kidney cells; carrying out alpaca kidney cell immortalized cell detection and identification; and obtaining the immortalized alpaca kidney cell line. The immortalized alpaca kidney cell constructed by the invention has the advantages of simple culture, repeated passage, good homogeneity, high expression quantity of constructed exogenous genes and the like, and provides a more powerful tool cell for research on alpaca immunity; the immortalized alpaca kidney cell line provides a new tool for virus infection mechanism, drug in-vitro function detection and antibody drug development and screening.

The invention discloses a serum-free full-suspension MDCK (Madin-Darby Canine Kidney) cell and application thereof in preparation of influenza vaccines, and belongs to the field of virology and biological medicines. The serum-free full-suspension MDCK cell is preserved in the China Center for Type Culture Collection, is classified and named as a canine kidney cell MDCK-JHS, and has a preservation number of CCTCC NO: C2024373. The invention further provides a method for culturing the influenza virus by using the cell line, high-titer amplification of the influenza virus can be realized, and the method is suitable for industrial production.

The invention discloses a variable region amino acid sequence of a monoclonal antibody of a West Nile virus non-structural protein NS1 and application of the variable region amino acid sequence, and belongs to the technical field of medicines. According to the invention, West Nile virus non-structural protein NS1 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the West Nile virus non-structural protein NS1 are screened from rabbit spleen cells through flow sorting, and a signal peptide and a variable region gene fragment of an antibody are cloned through reverse transcription-polymerase chain reaction; according to the present invention, the non-structural protein NS1 of flaviviridae flaviviridae virus is taken as a template, and is connected with a constant region gene to an expression vector, and after mammalian cell expression and purification, the monoclonal antibody which has high affinity and is not combined with the non-structural protein NS1 of other eight viruses of flaviviridae flaviviridae virus is obtained through enzyme-linked immunosorbent assay; the monoclonal antibody has application value in diagnosis and prevention and treatment of West Nile virus infection.

The invention discloses a larimichthys crocea IL-22 recombinant protein which is a larimichthys crocea IL-22 mature peptide sequence, and the amino acid sequence of the larimichthys crocea IL-22 recombinant protein is as shown in SEQ ID NO. 2. The recombinant protein is obtained by amplifying and coding gene segments of amino acids from 31st to 190th positions of large yellow croaker IL-22 mature peptide through PCR (Polymerase Chain Reaction), and transforming escherichia coli for heterologous expression. The larimichthys crocea IL-22 recombinant protein can activate a transcription factor STAT3 in a larimichthys crocea head kidney cell line (LYCK) and also can induce expression of inflammatory factors (IL-1beta, IL-6 and IL-8) in immune organs of larimichthys crocea, so that the larimichthys crocea IL-22 recombinant protein has an obvious immunoregulation effect and shows a good application prospect in research and development of aquatic immunomodulators.

The invention discloses a cat kidney suspension culture cell line suitable for serum-free suspension culture and application of the cat kidney suspension culture cell line. The name of the cell line is F81-B4, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.46350. After 50 generations of continuous subculture, the cells still can maintain the original proliferation level and cellular morphology, the cell number can reach 9.0 * 10 < 6 > / mL after the cells are subcultured at the density of 1.0 * 10 < 6 > / mL for three days, the multiplication time is 22-26 hours, and the cell proliferation speed is equivalent to that in a shake flask when the cells are amplified to a 10L bioreactor for culture. The cell line is highly susceptible to feline parvovirus, feline calicivirus, feline herpes virus, canine parvovirus and canine distemper virus, the virus content of a virus solution harvested 72 h after FPV virus inoculation can reach 107.5 TCID50 / mL, the virus content of a virus solution harvested 24 h after FCV virus inoculation can reach 1010.8 TCID50 / mL, the virus content of a virus solution harvested 48 h after FHV-1 virus inoculation can reach 107.5 TCID50 / mL, compared with an existing F81 adherent cell production process, the production process has the advantages that the production efficiency is high, and the production cost is low. The method has the characteristics of rapid lesion, short virus collection time and high titer. The cell matrix is an ideal cell matrix which can be used for culturing the three viruses.

The invention discloses a panda immortalized kidney cell line GPK-1 as well as a preparation method and application thereof, and belongs to the technical field of immortalized cells. The preparation method comprises the following steps: (1) collecting kidney tissues of dead pandas, and soaking the kidney tissues in a protective solution; (2) carrying out two-step digestion on the kidney tissue treated in the step (1); and (3) carrying out culture passage on the digested cells, then infecting the passage cells with lentiviruses carrying neomycin resistance genes and SV40-LT genes, and then screening to establish the panda immortalized kidney cell line. The invention provides a technology for efficiently separating and culturing panda nephrogenic cells, and establishes an immortalized panda nephrogenic cell line GPK-1. Compared with primary kidney cells of pandas, the GPK-1 retains normal karyotype and related molecular characteristics and is remarkably improved in the aspects of cell passage times, proliferation efficiency and transfection efficiency.

The invention discloses application of sodium tanshinone IIA sulfonate in preparation of anti-PEDV (porcine epidemic diarrhea virus) products, and belongs to the technical field of biology. According to the application disclosed by the invention, 2320 compounds are screened, and the tanshinone IIA sodium sulfonate is found to have a good inhibition effect on PEDV (Porcine Epidemic Diarrhea Virus). Tanshinone IIA sodium sulfonate with the concentration of 200 [mu] M is added in the process that African green monkey kidney cells are infected with PEDV in vitro, compared with a control group, the protein expression level, the mRNA content of N genes and the virus titer of PEDVN of an experimental group with the tanshinone IIA sodium sulfonate are obviously reduced, and it is indicated that the tanshinone IIA sodium sulfonate can be used for inhibiting infection and proliferation of the porcine epidemic diarrhea virus. The invention verifies that the tanshinone IIA sodium sulfonate can effectively inhibit the PEDV proliferation and the action mechanism thereof in an in-vitro environment, and the discovery not only widens the biological characteristics of the tanshinone IIA sodium sulfonate, but also provides a powerful experimental basis for the development of the tanshinone IIA sodium sulfonate as a novel potential anti-PEDV drug.

The invention belongs to the technical field of biological medicine, and particularly relates to an in-vitro fusion technology for multi-lineage human kidney organs and application thereof. The invention provides a method for realizing culture of multilineage kidney organs by fusing kidney units and ureteral bud organs in vitro. According to the in-vitro fusion technology of the kidney organoid reported by the invention, two organoid with different pedigree sources, namely the kidney unit and the ureteral bud, can be efficiently fused, a UB tubular structure is integrated into the kidney unit organoid, and the UB tubular structure starts from a single ureteral bud and is wrapped by kidney unit precursor cells in a similar in-vivo development process, and finally develops into a kidney with glomerulus and a plurality of kidney cells. The multi-lineage renal organ comprises a catheter, a proximal tube, a marrow tab thin section, a distal tube, a connecting tube and a ureteral bud with a single outlet. A framework is provided for an engineered renal unit and a smooth collection system, and the method is an important step for generating the functional renal tissue from the beginning.

The invention discloses a polyketone compound derived from actinomycetes as well as a preparation method and application thereof, and relates to the technical field of microbial natural product mining and biological medicine, and the key point of the technical scheme is that the invention discloses a novel polyketone compound Strepactone derived from actinomycetes Streptomyces sp. DP0001, and the molecular formula of the novel polyketone compound Strepactone is C25H38O5. The compound is obtained through strain fermentation, ethyl acetate extraction and multi-step chromatographic purification, and the structure is identified through ESI-MS, 1H NMR and 13C NMR. Experiments show that Strepactone has an inhibition effect on staphylococcus aureus and methicillin-resistant staphylococcus aureus and has remarkable inhibition activity on human non-small cell lung cancer A549 cells, the half inhibitory concentration IC50 of the Strepactone is 5.36 mu M, and the Strepactone has no obvious cytotoxic activity on human embryo kidney cells 293T cells at the concentration of 30 mu M. The compound provided by the invention can be used for preparing anti-drug-resistant bacteria drugs and anti-human non-small cell lung cancer drugs, and also provides a structural basis for the development of novel antibacterial and anti-tumor leading drugs.

Methods of identifying an enriched heterogeneous renal cell population having therapeutic potential, enriched heterogeneous renal cell populations having therapeutic potential and uses for same. In some embodiments, it includes a method of identifying an enriched heterogeneous renal cell population as having a therapeutic potential. In the method, it is determined whether cells of the enriched heterogeneous renal cell population express at least one: (i) ureteric bud and / or cap mesenchyme (UB / CM) marker; and / or (ii) podocyte marker.

The present invention relates to lipid nanoparticle (LNP) compositions, as well as diagnostic or therapeutic polynucleotides, such as TERT mRNA, that can be delivered in a formulation together with the LNP compositions to various tissue and cell types in the whole body of a mammal, such as, for example, TNP mRNA. Comprising stem cells, progenitor cells, germ cells, differentiated cells or terminally differentiated cells, cancer cells, endothelial cells, epithelial cells, splenic cells, hepatocells, kidney cells and / or osteoblasts, for example, for use in the diagnosis, prevention and / or treatment of a condition or disease.

The present disclosure provides an aggregate of kidney cells having improved expression of transporter genes. Some aspect of the present invention is an aggregate of kidney cells. The aggregate satisfies at least one of the following conditions. (a) The expression level of the OAT1 gene is 1 * 10 <-3 > or more (GAPDH ratio). (b) The expression level of the OAT3 gene is 1 * 10 <-4 > or more (GAPDH ratio). (c) The expression level of the OCT2 gene is 1 * 10 <-3 > or more (GAPDH ratio). (d) The expression level of MATE1 gene is 1 * 10 <-4 > or more (GAPDH ratio). (e) The expression level of the MATE2 gene is 1 * 10 <-5 > or more (GAPDH ratio). (f) The expression level of the MDR1 gene is 1 * 10 <-3 > or more (GAPDH ratio). (g) The expression level of the UART1 gene is 1 * 10 <-6 > or more (GAPDH ratio).

The invention discloses application of CFB polypeptide as a target spot in preparation of diabetic nephropathy diagnosis and treatment medicines, and belongs to the technical field of biological medicines. The invention provides application of CFB (circulating fluid bed)-sourced polypeptide in preparation of a medicine for treating diabetic nephropathy and application of the CFB-sourced polypeptide as a possible target in development of a novel diabetic nephropathy biomarker. According to the invention, a complement factor B-derived polypeptide which is significantly up-regulated in diabetic nephropathy is found through deep peptidomics analysis; furthermore, a functional experiment proves that the polypeptide shows remarkable anti-fibrosis activity in kidney cells for the first time, the active oxygen level can be reduced, and an HIF-1 alpha / glycolytic pathway can be regulated and controlled.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

A recombinant humanized collagen type III alpha-1 (rhCol III a1), and an expression vector and use thereof are provided, relating to the technical field of bioengineering. A sequence on positions 154 to 1,221 of a human type III collagen α chain is ligated to an optimized vector pcDNA3.1, a resulting optimized expression vector is transfected into a human embryonic kidney cell Expi293F, and then rhCol III a1 is secreted to form a fusion protein with a soluble green fluorescent protein (GFP). The expressed rhCol III a1 that forms the fusion protein with the GFP shows an activity of promoting the migration of BALB / c 3T3 cells, thus exhibiting a great application potential in the field of skin care.

The invention discloses a construction method of a human embryonic kidney cell monoclonal cell strain and application of the human embryonic kidney cell monoclonal cell strain in lentiviral vector production. The cell strain constructed by the invention adapts to suspension culture of a chemical component determination culture medium, is low in caking rate and rapid in growth, the toxin production level can reach 8-10 times that of a female parent cell, and the highest virus titer is about 1.99 E8TU / mL which is higher than the average yield of toxin production cell strains in the industry.

The invention discloses preparation and application of a therapeutic drug for preventing and treating heart failure or myocardial ischemia-reperfusion injury. Research results of the invention show that the exosome secreted by kidney cells after stimulation and induction of the drug-containing serum of Zhenwu decoction has a myocardial protection effect. Therefore, the invention provides a novel candidate drug for heart failure or myocardial ischemia-reperfusion injury.

The invention discloses a yellow fever virus envelope protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. Yellow fever virus envelope protein E expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the yellow fever virus envelope protein E are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the monoclonal antibody with high neutralizing activity and capable of completely protecting mice from yellow fever virus lethal attack is obtained by using the monoclonal antibody as a template, connecting the monoclonal antibody and the constant region gene to an expression vector, carrying out mammalian cell expression and purification, and carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse virus attack experiment, such that the monoclonal antibody has high neutralizing activity and can completely protect mice from yellow fever virus lethal attack; the monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention provides a composition for promoting ATP (adenosine triphosphate) generation and improving kidney energy metabolism by activating an AMPK / PGC-1alpha pathway. The composition is prepared from the following raw materials in parts by weight: 100 to 400 parts of herba cistanche, 50 to 200 parts of radix astragali seu hedysari, 25 to 100 parts of glycine betaine and 150 to 300 parts of alpha-ketoglutaric acid. The invention further provides a preparation method and application of the composition for improving ATP generation and improving kidney energy metabolism by activating the AMPK / PGC-1alpha pathway. Through combined use of cistanche, astragalus membranaceus, betaine and alpha-ketoglutaric acid, a multi-target synergistic mechanism of AMPK activation, metabolic substrate supplementation and epigenetic regulation is formed, the mitochondrial function and ATP generation of kidney cells are comprehensively improved, the limitation of existing single-component or chemical drugs is broken through, a safer and more efficient intervention strategy is provided for kidney energy metabolism disorders, and the clinical application prospect is broad. The invention provides an innovative solution for renal tubular energy disorder, has dual values of metabolic regulation and kidney protection, and conforms to the development trend of natural medicines. The invention belongs to the technical field of food and health care product processing.

And a means for further improving the evaluation precision is provided in the aspect of evaluating pharmacokinetics / toxicity and efficacy by using the cell aggregate of a plurality of samples. A plate having a plurality of holes in which a liquid and an aggregate of kidney cells are accommodated, the openings of the holes being covered with a film, and the ratio of the total volume of the aggregate and the liquid relative to the total volume of the holes being a predetermined ratio.

The invention discloses an emblic leafflower fruit milk processing technology optimization method based on a single factor and pharmacodynamic experiment, and belongs to the technical field of traditional Chinese medicine processing, and the method comprises the following steps: screening out optimal technological parameters through the single factor experiment: mixing emblic leafflower fruit and raw milk according to a material-liquid ratio of 1: 15, soaking at 45 + / -5 DEG C for 12 hours, cleaning milk stains, naturally air-drying for 2 hours, and drying at 50 DEG C for 24-48 hours until the water content is less than 6%. A liquid chromatography-tandem high-resolution mass spectrometry technology is adopted for analysis and displaying that the content of gallic acid, ellagic acid and corilagin in a processed product is remarkably reduced. Pharmacodynamic experiments prove that the toxicity of the processed product to WRL68 hepatocytes and 293T renal cells is weakened, the survival rate of the hepatocytes and the renal cells is increased along with reduction of the concentration of the components, and the toxicity reduction effect is achieved. The technological parameters are clear, the quality is stable, and a scientific basis is provided for standardized production and clinical safe medication of emblic leafflower fruit milk processing.

The invention belongs to the technical field of veterinary drugs, and particularly discloses application of laboldol serving as a medicinal ingredient in preparation of a medicine for preventing and treating FCV (Fine Calivirus) infection. According to the application disclosed by the invention, the experimental research finds that the Larburol can obviously inhibit the proliferation of FCV in cat kidney cells, and the median inhibitory concentration (IC50) of the Larburol is 1.87 mu M; in-vivo pharmacological experiments show that the laboldol significantly inhibits the replication of FCV in cats and alleviates symptoms induced by virus infection. Research results show that the laboldol can be used as a drug effect component and can be prepared into a preparation with an auxiliary agent, and the laboldol is used for preventing and treating diseases caused by FCV infection.

The invention relates to the technical field of diagnosis, in particular to a prognosis evaluation kit and evaluation method for renal cell carcinoma patients based on DNAJA1 protein expression quantity. The method for evaluating the prognosis and immune microenvironment state of the RCC patient based on the DNAJA1 expression level provided by the invention has good stability, accuracy and operability, can realize hierarchical management and individualized treatment guidance of patient risks, and has remarkable clinical and social values.

A recombinant humanized collagen type I alpha-1 (rhCol1A1), and an expression vector and use thereof are provided, belonging to the technical field of bioengineering. The rhCol1A1 has an amino acid sequence of SEQ ID NO: 1. This aim is to solve the problem of difficulty in expressing soluble full-length humanized collagen in Escherichia coli prokaryotic expression systems, and differences between the recombinant collagen and humanized collagen in yeast expression systems. It is proposed that the rhCol1A1 chain is expressed in Expi293F™ human embryonic kidney cells, and the protein expression level is increased using a fusion expression plasmid, enabling the expression of full-length humanized collagen type I alpha 1 chain. Activity studies have shown that the expressed rhCol1A1 exhibits a desirable activity in promoting cell migration, and may be widely used in the fields of biomedicine, tissue engineering, skin care, and food.

The present invention discloses a giant panda immortalized kidney cell line GPK‑1, a preparation method and a use thereof, and belongs to the field of immortalized cell technology. The preparation method is as follows: (1) collecting kidney tissue of a dead giant panda and immersing it in a protective solution; (2) performing two-step digestion on the kidney tissue treated in step (1); (3) culturing and propagating the digested cells, and then infecting the propagated cells with a lentivirus carrying a neomycin resistance gene and an SV40‑LT gene, and then screening and establishing a giant panda immortalized kidney cell line. The present invention provides a technology for efficiently isolating and culturing giant panda kidney-derived cells, and establishes an immortalized giant panda kidney-derived cell line GPK‑1. Compared with primary giant panda kidney cells, GPK‑1 retains normal karyotype and related molecular characteristics, and has been significantly improved in terms of cell passage times, proliferation efficiency and transfection efficiency.

The application discloses application of sodium butyrate in preparation of a medicine for preventing and treating grass carp hemorrhagic disease, wherein a structural formula of the sodium butyate is molecular formula C4H7NaO2, and a CAS number is 156-54-7; and the application further provides a medicine composition which comprises an effective dose of the sodium butyrate as an active ingredient, and further comprises a pharmaceutically acceptable carrier or excipient, and the dosage form comprises tablets, granules, powders, powders, suspensions, oral liquids, and the concentration of the sodium butyrate is 0.1-20 mM. Through a cell experiment, it is found that the sodium butyrate can significantly inhibit replication of grass carp reovirus in grass carp kidney cells, and improve expression of immune genes of the grass carp kidney cells, and it is proved that the sodium butyrate has a high efficient inhibiting effect on infection of the grass carp reovirus, and has the advantages of high safety and wide application prospect for preparing the medicine for preventing and treating the grass carp hemorrhagic disease caused by the grass carp reovirus.

The application discloses a kind of kidney cell cancer patient prognosis risk prediction methods based on multi-modal deep learning.The present application processes whole field digital pathology section (WSI) image and pathological diagnosis report by deep learning algorithm, extracts text features using natural language processing model, extracts image features using computer vision model and ABMIL network, and carries out multi-modal feature fusion through Cross-attention Transformer network, and finally outputs the survival risk curve of patient changes with time in combination with Weibull survival function, for assisting doctor to carry out more accurate prognosis evaluation and survival analysis.

The invention relates to the technical field of preparation of antibacterial materials, in particular to a two-dimensional nickel (II) coordination polymer as well as a preparation method and antibacterial application thereof. The preparation method comprises the following steps: mixing a dpb solution, a btc solution, a Ni (NO3) 2 solution, acetonitrile and water, carrying out a solvothermal reaction for 4-5 days, carrying out natural cooling crystallization, washing and drying to obtain [Ni3 (dpb) 2 (btc) 2 (H2O) 2] n, and according to the complex, nickel (II) has two coordination modes, and nickel (II) is coordinated with carboxyl oxygen atoms of two trimesic acid, oxygen atoms of two water molecules and nitrogen atoms of two ligands; nickel 2 (II) is coordinated with three nitrogen atoms of a ligand and three oxygen atoms of two trimesic acids to form a one-dimensional ladder-shaped chain structure, and the ladder-shaped chain is further bridged with the ligand to form a two-dimensional layered structure. The compound has very good thermal stability, has a good inhibition effect on staphylococcus aureus and escherichia coli, is non-toxic to human embryo kidney cells in 24 hours and 48 hours, and can be used as a bacteriostatic drug material carrier in the aspect of medicine.

The invention discloses a folium cortex eucommiae extract and application of the folium cortex eucommiae extract in prevention and treatment of adriamycin nephropathy, and relates to the technical field of medicines, the folium cortex eucommiae extract is prepared from dried folium cortex eucommiae through water extraction, heating at 65 DEG C, ultrasonic assistance and vacuum freeze drying, LC-MS / MS analysis shows that the folium cortex eucommiae extract contains no less than 200 components, the components mainly comprise flavonoids, terpenes and phenylpropanoids, and the content of the flavonoids, the terpenes and the phenylpropanoids is no less than 100%. The folium cortex eucommiae extract has no obvious cytotoxicity to HK-2 and HBZY-1 cells under the concentration of 0-1500mu g / mL, can be used for preparing medicines for preventing and treating adriamycin nephropathy, inhibits kidney cell apoptosis by down-regulating Bax and up-regulating Bcl-2 and obviously reduces the levels of IL-6, IL-1beta and TNF-alpha in serum, and in an animal model, 150-600mg / kg of the folium cortex eucommiae extract is continuously administrated for 21-30 days in an intragastric manner, so that the effect of preventing and treating adriamycin nephropathy is achieved. The traditional Chinese medicine composition can effectively relieve weight loss, reduce urine protein, serum creatinine and urea nitrogen, increase albumin and improve kidney pathological injury, and is suitable for relieving kidney toxicity in a prophylactic or therapeutic mode in subjects receiving adriamycin chemotherapy.